Montoya, Jose G, Kogelnik, Andreas M, Bhangoo, Munveer et al. · Journal of medical virology · 2013 · DOI
This study tested whether a antiviral medication called valganciclovir could help ME/CFS patients who had evidence of past infection with two common viruses (HHV-6 and EBV). Thirty patients received either the medication or placebo for 6 months. Those taking valganciclovir showed improvements in mental fatigue, overall fatigue, and cognitive function within the first 3 months, and these improvements lasted through the end of the study. The medication also produced changes in immune cell counts that suggest the patient's immune system was shifting toward a different state.
This is one of the few randomized controlled trials testing a pathogen-directed treatment in ME/CFS, addressing the hypothesis that reactivated herpesviruses may contribute to symptoms in a subset of patients. If confirmed in larger studies, valganciclovir or similar antivirals could become the first evidence-based pharmaceutical option for certain ME/CFS patients, potentially transforming clinical management.
This study does not establish that HHV-6 or EBV reactivation causes ME/CFS, only that reducing viral burden may help some patients with elevated antibody titers. The small sample size (n=30) and lack of statistical significance on the primary endpoint (MFI-20 total score) limit generalizability. The unchanged viral IgG titers suggest the mechanism may not be simple viral suppression, leaving the true biological mechanism unclear.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →